The Michigan Genetic Hereditary Testing (MiGHT) study’s innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trial

BACKGROUND: Although most cancers are sporadic, germline genetic variants are implicated in 5–10% of cancer cases. Clinical genetic testing identifies pathogenic germline genetic variants for hereditary cancers. The Michigan Genetic Hereditary Testing (MiGHT) study is a three-arm randomized clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerido, Lynette Hammond, Griggs, Jennifer J., Resnicow, Ken, Kidwell, Kelley M., Delacroix, Emerson, Austin, Sarah, Hanson, Erika N., Bacon, Elizabeth, Koeppe, Erika, Goodall, Stefanie, Demerath, Matthew, Rizzo, Elizabeth A., Weiner, Shayna, Hawley, Sarah T., Uhlmann, Wendy R., Roberts, J. Scott, Stoffel, Elena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911941/
https://www.ncbi.nlm.nih.gov/pubmed/36765432
http://dx.doi.org/10.1186/s13063-023-07125-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911941/
https://www.ncbi.nlm.nih.gov/pubmed/36765432
http://dx.doi.org/10.1186/s13063-023-07125-2

Ejemplares similares